Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,340.00
Bid: 12,360.00
Ask: 12,362.00
Change: -76.00 (-0.61%)
Spread: 2.00 (0.016%)
Open: 12,234.00
High: 12,370.00
Low: 12,164.00
Prev. Close: 12,416.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-SAP drags down German shares, COVID-19 worries weigh on broader Europe

Mon, 26th Oct 2020 09:43

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* German DAX closes at lowest in almost 4 months

* SAP cutting its 2020 outlook, posts worst fall in 24 years

* SAP's pessimism dents hopes of global recovery - analyst

* Oil drop pressures energy stocks
(Updates to close)

By Sruthi Shankar and Susan Mathew

Oct 26 (Reuters) - German shares closed at their lowest in
nearly four months on Monday as Europe's most valuable tech
firm, SAP, experienced its worst trading day in 24
years after cutting its 2020 outlook.

The German DAX fell 3.7% as SAP slumped
almost 22% after abandoning medium-term profitability targets
and cautioning that its business would take longer than expected
to recover from the pandemic hit.

"SAP's pessimism does not bode well for hopes for the global
economic recovery to continue," said Edward Moya, senior market
analyst at OANDA, New York.

"If tech goes, the deteriorating outlook due to virus spread
will likely yield massive risk aversion as investors head for
the sidelines instead of rotating into cyclicals."

The wider European tech index slid 7.4%.

SAP's results came as a blip in the third-quarter earnings
season, which has been largely better than feared.

Meanwhile, fresh COVID-19-induced restrictions in Italy and
Spain to curb a resurgence in cases weighed on the rest of
Europe, with the pan-European STOXX 600 index closing
at a one-month low, down 1.8%.

Europe on Saturday became the second region after Latin
America to surpass 250,000 deaths, according to a Reuters tally.

The euro zone blue-chip index fell nearly 3%,
while Europe's travel and leisure sector, worst hit by the
movement curbs, was down 3.3%.

Nick Nelson, head of European equity strategy at UBS, said
the Swiss bank's target for STOXX 600 into the year-end is 340
points, about 4.5% below the current level, in part due to the
impact of the latest round of restrictions.

Surveys of euro zone purchasing managers last week showed
economic activity slipped back into decline in October,
heightening expectations for a double-dip recession as a second
wave of virus sweeps across the continent.

Globally, risk appetite was sapped by worries over slow
progress on a new U.S. stimulus bill and a looming presidential
election.

Milan's blue-chip index fell 1.8% even as ratings
agency Standard and Poor's upgraded Italy's sovereign outlook to
stable from negative.

Oil majors Total and Royal Dutch Shell
fell over 2.8% as crude prices slumped more than 3% on demand
worries.

Healthcare stocks remained supportive, with
AstraZeneca gaining 1.7% after it resumed the U.S. trial
of its experimental COVID-19 vaccine.

French stocks dipped 1.9%. Turkish leader Tayyip
Erdogan asked his compatriots to stop buying French goods on
Monday in the latest expression of anger in the Muslim world
over images being displayed in France of the Prophet Mohammad,
which some Muslims consider blasphemous.
(Reporting by Sruthi Shankar in Bengaluru; Editing by Sriraj
Kalluvila and Emelia Sithole-Matarise)

More News
27 Jul 2023 21:08

IN BRIEF: Astra drug approved while another shows promise

AstraZeneca PLC - Cambridge-based pharmaceutical firm - Says Soliris approved in EU for treatment of refractory generalised myasthenia gravis in those aged between six and 17. "This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU," AstraZeneca says. Myasthenia gravis is a disease that causes muscle weakness. Separately, Astra says Enhertu shows meaningful progression-free survival and overall survival in some cancer sufferers. The measures are two secondary endpoints of a phase II trial. Enhertu is being jointly-developed by Astra and Daiichi Sankyo Co Ltd.

Read more
27 Jul 2023 18:07

Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

Q2 revenue at $11.23 bln, misses analysts' estimate

*

Read more
25 Jul 2023 12:07

IN BRIEF: OTAQ names interim finance chief with incumbent to move on

OTAQ PLC - Lancaster, England-based marine technology company, focused on offshore oil and gas industries and aquaculture - Chief Financial Officer Matt Enright resigns effective July 31, to assume a new role outside OTAQ. He was hired as CFO in April 2020. OTAQ appoints Justine Dowds, previously managing director at GB3 Ltd until May, as interim CFO. Dowds was also finance director at Pool Aviation Ltd from 2007 to 2015, and prior to that was financial controller at United Utilities Group PLC and an accountant at AstraZeneca PLC. Enright says: "I believe the company is now well placed to benefit from the investments in resource and products made over the past three years, placing OTAQ on a sound growth path."

Read more
20 Jul 2023 14:35

Activist investor Elliott takes stake in drug manufacturer Catalent - source

LONDON, July 20 (Reuters) - Activist investor Elliott Investment has taken a stake in contract drugmaker Catalent , a source familiar with the matter told Reuters on Thursday.

Read more
18 Jul 2023 08:10

AstraZeneca, Sanofi infant respiratory treatment gets US approval

(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.

Read more
18 Jul 2023 07:48

LONDON BRIEFING: Ocado backs annual guidance as interim loss widens

(Alliance News) - Stocks in London are set to tread water on Tuesday, as investors look ahead to US corporate earnings and economic data.

Read more
18 Jul 2023 06:04

Rishi Sunak to meet bosses at inaugural Business Council gathering

(Alliance News) - Bosses from AstraZeneca PLC, Alphabet Inc's Google, Shell PLC and other major companies will gather in Downing Street on Tuesday for the first meeting of Rishi Sunak's Business Council.

Read more
17 Jul 2023 22:30

British prime minister seeks to win back corporate confidence with new business council

LONDON, July 17 (Reuters) - British Prime Minister Rishi Sunak will hold the first meeting of his new business council on Tuesday, in a bid to support his pledge to grow the economy and fend off attempts by the opposition Labour Party to win over the business community.

Read more
17 Jul 2023 19:33

US FDA approves AstraZeneca and Sanofi's Beyfortus for RSV in infants

(Alliance News) - AstraZeneca PLC and Sanofi SA on Monday said the US Food & Drug Administration has approved the use of Beyfortus, or nirsevimab, in the US.

Read more
14 Jul 2023 09:13

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
14 Jul 2023 08:56

LONDON MARKET OPEN: Stocks mixed ahead of US bank earnings

(Alliance News) - Stock prices in London opened mixed on Friday, after a strong run this week, while investors wait to see how major US banks fared in the second quarter of the year.

Read more
14 Jul 2023 07:56

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Read more
12 Jul 2023 12:08

Astra, Daiichi get China approval for Enhertu breast cancer treatment

(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday its metastatic breast cancer treatment with AstraZeneca PLC was approved in China as a monotherapy for adult patients.

Read more
12 Jul 2023 09:27

LONDON BROKER RATINGS: UBS raises AstraZeneca; RBC cuts Bunzl

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
12 Jul 2023 08:45

LONDON MARKET OPEN: FTSE 100 higher as UK banks pass BoE stress tests

(Alliance News) - European markets were trading higher on Wednesday, in a sign of cautious optimism ahead of US inflation data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.